102 related articles for article (PubMed ID: 2292053)
21. The Ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro.
Batova A; Kamps A; Gillies SD; Reisfeld RA; Yu AL
Clin Cancer Res; 1999 Dec; 5(12):4259-63. PubMed ID: 10632368
[TBL] [Abstract][Full Text] [Related]
22. Neurocytotoxic antibodies in serum of patients with systemic lupus erythematosus.
Bluestein HG
Proc Natl Acad Sci U S A; 1978 Aug; 75(8):3965-9. PubMed ID: 279013
[TBL] [Abstract][Full Text] [Related]
23. A naturally occurring complement dependent human IgM macroglobulin inhibitory to Ehrlich ascites tumor cells.
Goff MM; Armentrout SA
J Clin Lab Immunol; 1982 Dec; 9(3):163-7. PubMed ID: 7166749
[TBL] [Abstract][Full Text] [Related]
24. Cytotoxic activity against human neuroblastoma and melanoma cells mediated by IgM antibodies derived from peripheral blood of healthy donors.
Devarapu SK; Mamidi S; Plöger F; Dill O; Blixt O; Kirschfink M; Schwartz-Albiez R
Int J Cancer; 2016 Jun; 138(12):2963-73. PubMed ID: 26830059
[TBL] [Abstract][Full Text] [Related]
25. The novel chimeric anti-NCAM (neural cell adhesion molecule) antibody ch.MK1 displays antitumor activity in SCID mice but does not activate complement-dependent cytolysis (CDC).
Klehr M; Koehl U; Mühlenhoff M; Tawadros S; Fischer T; Schomäcker K; Heuckmann JM; Bochennek K; Jensen M
J Immunother; 2009 Jun; 32(5):442-51. PubMed ID: 19609236
[TBL] [Abstract][Full Text] [Related]
26. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells.
Cheung NK; Saarinen UM; Neely JE; Landmeier B; Donovan D; Coccia PF
Cancer Res; 1985 Jun; 45(6):2642-9. PubMed ID: 2580625
[TBL] [Abstract][Full Text] [Related]
27. Expansion of natural killer cells in mice transgenic for IgM antibody to ganglioside GD2: demonstration of prolonged survival after challenge with syngeneic tumor cells.
Kawashima I; Yoshida Y; Taya C; Shitara H; Yonekawa H; Karasuyama H; Tada N; Furukawa K; Tai T
Int J Oncol; 2003 Aug; 23(2):381-8. PubMed ID: 12851687
[TBL] [Abstract][Full Text] [Related]
28. Complement-mediated cytolytic activity associated with cytomegalovirus complement-fixing IgM antibody.
Booth JC; Mohammed HS
J Med Virol; 1988 Mar; 24(3):351-9. PubMed ID: 2835430
[TBL] [Abstract][Full Text] [Related]
29. Human IgM monoclonal antibodies reactive with HIV-1-infected cells generated using a trans-chromosome mouse.
Okada N; Yin S; Asai S; Kimbara N; Dohi N; Hosokawa M; Wu X; Okada H
Microbiol Immunol; 2005; 49(5):447-59. PubMed ID: 15905607
[TBL] [Abstract][Full Text] [Related]
30. Isolation of a natural cytotoxic IgM "antibody" in human serum sensitizing L cells to complement.
Bolande RP; Mayer DC
Proc Soc Exp Biol Med; 1989 Sep; 191(4):387-90. PubMed ID: 2771965
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of complement-mediated porcine endothelial cell cytotoxicity by human IgM natural antibody.
Dalmasso AP; He T; Benson BA
Transplant Proc; 1996 Apr; 28(2):535. PubMed ID: 8623251
[No Abstract] [Full Text] [Related]
32. Human natural immunoglobulin M antibodies induce apoptosis of human neuroblastoma cells by binding to a Mr 260,000 antigen.
David K; Ollert MW; Vollmert C; Heiligtag S; Eickhoff B; Erttmann R; Bredehorst R; Vogel CW
Cancer Res; 1999 Aug; 59(15):3768-75. PubMed ID: 10446994
[TBL] [Abstract][Full Text] [Related]
33. Naturally occurring humoral cytotoxicity against neuroblastoma (NB) cells in healthy persons and NB patients.
Erttmann R; Schmitt C; Ollert MW; David K; Bredehorst R; Vogel CW
Pediatr Hematol Oncol; 1996; 13(6):545-8. PubMed ID: 8940738
[TBL] [Abstract][Full Text] [Related]
34. Complement depletion in vitro limits monoclonal antibody 6-19-dependent complement-mediated killing of tumor cells in bone marrow.
Duerst RE; Rose D; Frantz CN
Exp Hematol; 1991 Oct; 19(9):863-7. PubMed ID: 1893961
[TBL] [Abstract][Full Text] [Related]
35. Removal of terminal alpha-galactosyl residues from xenogeneic porcine endothelial cells. Decrease in complement-mediated cytotoxicity but persistence of IgG1-mediated antibody-dependent cell-mediated cytotoxicity.
Watier H; Guillaumin JM; Piller F; Lacord M; Thibault G; Lebranchu Y; Monsigny M; Bardos P
Transplantation; 1996 Jul; 62(1):105-13. PubMed ID: 8693523
[TBL] [Abstract][Full Text] [Related]
36. Expression of Gal alpha(1,3)gal on neonatal porcine islet beta-cells and susceptibility to human antibody/complement lysis.
Rayat GR; Rajotte RV; Elliott JF; Korbutt GS
Diabetes; 1998 Sep; 47(9):1406-11. PubMed ID: 9726228
[TBL] [Abstract][Full Text] [Related]
37. Anti-neuroblastoma monoclonal antibodies which do not bind to bone marrow cells.
Frantz CN; Duerst RE; Ryan DH; Gelsomino NL; Constine LS; Gregory PK
Prog Clin Biol Res; 1985; 175():485-99. PubMed ID: 3887430
[TBL] [Abstract][Full Text] [Related]
38. Cytotoxicity of lymphokine-activated killer cells against human neuroblastoma cells: modulation by neuroblast differentiation.
Duan DS; Farmer D; Rayner AA; Sadee W
Med Pediatr Oncol; 1990; 18(4):339-44. PubMed ID: 1972538
[TBL] [Abstract][Full Text] [Related]
39. Expression of a 260 kDa neuroblastoma surface antigen, the target of cytotoxic natural human IgM: correlation to MYCN amplification and effects of retinoic acid.
David K; Ehrhardt A; Ollert MW; Erttmann R; Bredehorst R; Vogel CW
Eur J Cancer; 1997 Oct; 33(12):1937-41. PubMed ID: 9516828
[TBL] [Abstract][Full Text] [Related]
40. Experimental study of the maternal effects on tumor immunity of infant mice with C1300 mouse neuroblastoma.
Sakamoto I; Kawakatsu H; Kidowaki T; Matumura T; Sugimoto T; Sawada T
J Pediatr Surg; 1988 Apr; 23(4):350-3. PubMed ID: 3385589
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
